DOUGLAS LANDY: Open Payments
NPI 1104893494 · NEW CITY, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,380 in 78 payments from 7 companies in 2025. Trend: 2023 $3,246 · 2024 $524 · 2025 $1,380
Food & beverage: $1,380
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 22 | $592 |
| Neurocrine BioSciences, Inc. | 19 | $285 |
| Alkermes, Inc. | 19 | $226 |
| ABBVIE INC. | 12 | $163 |
| Otsuka America Pharmaceutical, Inc. | 3 | $48 |
| Janssen Pharmaceuticals, Inc | 2 | $44 |
| Supernus Pharmaceuticals, Inc. | 1 | $23 |
Products named: COBENFY, INGREZZA, VRAYLAR, LYBALVI, ARISTADA, INVEGA SUSTENNA, REXULTI, Qelbree.
Industry payments across NY — which companies pay providers there.
